We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen announced that it is acquiring ChemoCentryx, a developer of oral therapies to treat autoimmune diseases, inflammatory disorders and cancer, for approximately $3.7 billion. Read More
Johnson & Johnson (J&J) disclosed that it has pursued arbitration against beleaguered vaccine manufacturer Emergent BioSolutions for alleged breach of contract. Read More
Vertex Pharmaceuticals has doubled down on its patent fight against Lupin over the company’s plan to market a generic version of Vertex’s cystic fibrosis treatment Kalydeco (ivacaftor). Read More
Kelun-Biotech will receive an upfront payment of $35 million and is eligible to receive future milestone payments totaling up to $901 million. Read More
Amneal Pharmaceuticals subsidiary Impax Laboratories has agreed to pay $145 million to settle allegations it partnered with Endo International to illegally delay the launch of a generic of Endo’s opioid painkiller Opana ER (oxymorphone). Read More
Following their three-year partnership, Ultragenyx Pharmaceutical has acquired GeneTx for an upfront payment of $75 million plus undisclosed future milestone and royalty payments. Read More
One in six men over 50 have symptoms of testosterone deficiency, but too few of them receive appropriate treatment, said Grünenthal CEO Gabriel Baertschi. Read More